サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1765417

希少血液学の世界市場

Rare Hematology

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
希少血液学の世界市場
出版日: 2025年07月09日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

希少血液学の世界市場は2030年までに253億米ドルに達する見込み

2024年に190億米ドルと推定される希少血液学の世界市場は、2024年から2030年にかけてCAGR 4.9%で成長し、2030年には253億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである血漿由来因子は、CAGR 5.0%を記録し、分析期間終了までに182億米ドルに達すると予想されます。組換え因子セグメントの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は52億米ドルと推定、中国はCAGR 4.6％で成長すると予測

米国の希少血液学市場は、2024年に52億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに40億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.6%となります。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と4.2%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の希少血液学市場 - 主要動向と促進要因まとめ

希少血液学市場とは何か、なぜヘルスケアで勢いを増しているのか？

希少血液学市場は、血友病、鎌状赤血球症、サラセミア、発作性夜間ヘモグロビン尿症（PNH）、各種貧血などの疾患を含む希少血液疾患の診断、治療、管理に焦点を当てています。これらの疾患は、世界人口のごく一部、通常は2,000人に1人以下の割合で罹患するため、希少疾患に分類されます。各希少血液疾患の患者数は比較的少ないが、慢性疾患であること、複雑な管理が必要であること、治療費が高額であることなどから、これらの疾患がヘルスケアシステムに与える累積的影響は大きいです。従来、希少血液疾患の患者は、限られた治療選択肢と低レベルの研究投資に直面してきました。しかし、最近のゲノミクス、バイオテクノロジー、個別化医療の動向はこのシナリオを変えつつあり、新規治療法の発見と患者の転帰の改善を目指した研究開発の急増につながっています。その結果、希少血液学市場は、認知度の向上、支援政策、最先端治療法の導入により勢いを増しており、これらの課題の管理を再構築しつつあります。

患者支援団体の台頭や、ヘルスケアプロバイダー、製薬会社、規制当局間の協力体制の強化も、希少血液学市場の成長に寄与しています。National Organization for Rare Disorders（NORD）やEuropean Hematology Association（EHA）などの団体は、研究資金の増額、治療へのアクセス改善、患者ケアの強化の提唱に力を発揮しています。こうした取り組みにより、製薬会社は市場規模が小さいにもかかわらず、希少疾患の治療薬であるオーファンドラッグの開発に投資するようになりました。世界各国の政府は、こうした特殊な治療法の開発を奨励するため、市場独占権、税額控除、迅速な承認プロセスなど、さまざまなインセンティブを導入しています。その結果、希少血液学市場には、遺伝子治療やモノクローナル抗体から先進生物製剤に至るまで、新たな治療オプションが着実に流入しています。このような革新的なソリューションの出現により、ヘルスケアプロバイダーは希少な血液疾患を管理する能力が向上し、以前は治療の選択肢が限られていた、あるいは全くなかった患者のQOLが向上しています。

技術の進歩は希少血液疾患の治療状況をどのように変えているのか？

技術の進歩は、希少血液疾患の治療法の開発において変革的な役割を果たし、これらの疾患の診断と治療の方法に革命をもたらしました。この分野で最も画期的な技術革新のひとつが遺伝子治療の登場です。遺伝子治療は、多くの希少血液疾患の原因となっている根本的な遺伝子変異を標的とするもので、長期的な治療、あるいは根治的な治療の可能性を提供するものです。たとえば血友病の治療では、遺伝子治療によって欠陥遺伝子の機能的コピーを導入し、患者が必要な凝固因子を自然に産生できるようにすることで、定期的な凝固因子補充療法の必要性を減らすかなくすことを目指しています。同様に、CRISPR-Cas9のような遺伝子編集技術は、鎌状赤血球症やβサラセミアに対する潜在的治療法として研究されており、初期の臨床試験では有望な結果が得られています。これらの技術は、希少血液疾患の治療パラダイムを変革する可能性を秘めており、これまで対症療法に頼ってきた患者に希望を与えるものです。

遺伝子治療に加え、生物学的製剤や標的治療薬の進歩は、希少血液疾患に対する治療の選択肢を広げています。例えば、モノクローナル抗体は、疾患の進行に関与する特定の経路やタンパク質を標的とするように開発されており、副作用の少ない、より正確な治療アプローチを提供しています。PNHのような疾患では、補体阻害剤のような標的療法が導入され、溶血や血栓症のリスクを効果的に低減し、患者の予後を大幅に改善しています。さらに、個別化医療が希少血液学に統合されたことで、ヘルスケアプロバイダーは個人の遺伝子プロファイルに基づいて治療をオーダーメイドできるようになり、より高い有効性と安全性が確保されるようになりました。診断技術も進化しており、次世代シーケンサー（NGS）やハイスループットスクリーニング法により、希少な遺伝子変異をより正確かつ迅速に同定することが可能になっています。このような技術的進歩は、診断の精度を高めるだけでなく、早期発見と早期介入を促進し、希少血液疾患をより効果的に管理する上で極めて重要です。

希少血液学市場における新たな治療法の採用を促進する要因は何か？

希少血液学市場における新規治療の採用増加には、希少血液疾患の有病率の増加、医学研究の進歩、有利な規制枠組みなど、いくつかの要因が寄与しています。希少血液疾患の罹患率の増加は、診断能力の向上が一因であり、これによりこれらの疾患の検出率が高まり、より正確に分類されるようになりました。より多くの患者が正確に診断されるようになったことで、従来の治療を超える革新的な治療に対する需要が高まっています。同時に、医学研究、特にゲノムとバイオテクノロジーの分野の進歩により、より効果的で的を絞った治療法の開発が可能になっています。臨床試験でこれらの治療法が成功したことで、製薬企業は希少血液学に多額の投資を行うようになり、患者にとって新しく改善された治療法の選択肢が増えることにつながっています。

治療法導入のもう一つの重要な推進力は、規制環境の整備です。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、希少疾患の治療法開発に伴う特有の課題を認識し、希少疾病用医薬品ステータスや画期的治療薬指定などの特別な指定を設けています。これらの制度は、市場の独占期間の延長、審査プロセスの迅速化、規制当局への手数料の減免などのインセンティブを提供し、企業にとって希少血液学領域での医薬品開発を進める上でより魅力的なものとなっています。さらに、患者支援団体の影響力の高まりは、利用可能な治療法に関する認知度の向上と情報へのアクセスの改善につながり、患者やその家族が専門的な治療や新規治療法を求める力を与えています。その結果、特にこれまで治療法の選択肢が限られていた、あるいは全くなかった患者集団の間で、こうした新しい治療法が受け入れられつつあります。これらの要因が相まって、希少血液学市場において、より高い採用率が促進され、新しい治療法の裾野が広がっています。

希少血液学の世界市場成長の原動力は？

世界の希少血液学市場の成長は、希少疾患研究への注目の高まり、治療技術の進歩、ヘルスケア政策の進化など、いくつかの要因によってもたらされます。主な成長要因の1つは、製薬会社やバイオテクノロジー企業による研究開発投資の増加です。有利な規制上の優遇措置や患者の需要の高まりに後押しされ、企業は希少血液疾患の革新的な治療法の発見と開発に多大な資源を投入しています。その結果、遺伝子治療薬や酵素補充薬から次世代生物製剤や低分子医薬品に至るまで、新たな治療薬が着実に開発されています。市場はまた、より効果的な疾患モデリング、薬剤スクリーニング、臨床試験を可能にする技術革新からも恩恵を受けており、それによって開発プロセスが加速され、新しい治療法がより迅速に市場に投入されるようになっています。

進化するヘルスケア政策も市場成長の重要な促進要因です。多くの国では、血液疾患を含む希少疾患患者の診断、治療、ケアを改善することを目的とした国家希少疾患計画や政策を導入しています。このような政策には、研究資金の増加、専門医療センターの開発支援、先進治療への患者アクセスの改善などの取り組みが含まれることが多くあります。さらに、学術界、産業界、患者団体間の連携により、より協力的な研究環境が育まれ、この分野における技術革新のペースが加速しています。もう一つの成長要因は、希少な血液疾患の増加であり、これにより専門的治療を必要とする患者数が増加しています。認知度の向上と診断能力の向上が診断率の向上に寄与し、それが標的治療と包括的ケアソリューションの需要を促進しています。このような要因が重なる中、世界の希少血液学市場は、強力な技術革新のパイプライン、強化された規制の枠組み、患者の転帰と生活の質を改善することへのますます高まる焦点に支えられ、継続的な成長を遂げる態勢を整えています。

セグメント

製品タイプ（血漿由来因子、遺伝子組換え因子）、年齢層（成人（18歳以上））、小児（0～17歳）

調査対象企業の例

  • Alexion Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • CSL Behring
  • Novo Nordisk A/S
  • PRA Health Sciences
  • Shire PLC

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP16742

Global Rare Hematology Market to Reach US$25.3 Billion by 2030

The global market for Rare Hematology estimated at US$19.0 Billion in the year 2024, is expected to reach US$25.3 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Plasma Derived Factors, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$18.2 Billion by the end of the analysis period. Growth in the Recombinant Factors segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.2 Billion While China is Forecast to Grow at 4.6% CAGR

The Rare Hematology market in the U.S. is estimated at US$5.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.0 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Rare Hematology Market - Key Trends & Drivers Summarized

What Is The Rare Hematology Market and Why Is It Gaining Momentum in Healthcare?

The Rare Hematology market focuses on the diagnosis, treatment, and management of rare blood disorders, which include conditions such as hemophilia, sickle cell disease, thalassemia, paroxysmal nocturnal hemoglobinuria (PNH), and various types of anemia. These diseases are classified as rare because they affect a small percentage of the global population, typically less than 1 in 2,000 individuals. Although the patient population for each rare hematologic condition is relatively small, the cumulative impact of these diseases on healthcare systems is significant due to their chronic nature, complex management requirements, and the high cost of treatments. Traditionally, patients with rare hematologic conditions have faced limited treatment options and low levels of research investment. However, recent advancements in genomics, biotechnology, and personalized medicine are changing this scenario, leading to a surge in research and development activities aimed at discovering novel therapies and improving patient outcomes. As a result, the Rare Hematology market is gaining momentum, driven by increasing awareness, supportive policies, and the introduction of cutting-edge treatments that are reshaping the management of these challenging conditions.

The rise of patient advocacy groups and increased collaboration between healthcare providers, pharmaceutical companies, and regulatory bodies have also contributed to the growth of the Rare Hematology market. Organizations such as the National Organization for Rare Disorders (NORD) and the European Hematology Association (EHA) have been instrumental in advocating for more research funding, better access to treatments, and enhanced patient care. These efforts have spurred pharmaceutical companies to invest in the development of orphan drugs-medications designed to treat rare conditions-despite the smaller market size. Governments around the world have introduced various incentives, including market exclusivity, tax credits, and fast-track approval processes, to encourage the development of these specialized treatments. As a result, the Rare Hematology market has seen a steady influx of new therapeutic options, ranging from gene therapies and monoclonal antibodies to advanced biologics. With the advent of these innovative solutions, healthcare providers are better equipped to manage rare hematologic disorders, improving the quality of life for patients who previously had limited or no treatment options.

How Are Technological Advancements Transforming The Treatment Landscape Of Rare Hematologic Disorders?

Technological advancements have played a transformative role in the development of therapies for rare hematologic disorders, revolutionizing the way these diseases are diagnosed and treated. One of the most groundbreaking innovations in this field is the advent of gene therapy. Gene therapies target the underlying genetic mutations responsible for many rare blood disorders, offering the potential for long-term or even curative treatments. For example, in the treatment of hemophilia, gene therapies aim to introduce a functional copy of the defective gene, enabling patients to produce the necessary clotting factors naturally, thereby reducing or eliminating the need for regular factor replacement therapy. Similarly, gene-editing technologies such as CRISPR-Cas9 are being explored as potential treatments for sickle cell disease and beta-thalassemia, with early clinical trials showing promising results. These technologies have the potential to transform the treatment paradigm for rare hematologic disorders, offering hope for patients who have historically relied on symptomatic treatments.

In addition to gene therapy, advances in biologics and targeted therapies are expanding the range of treatment options available for rare hematologic conditions. Monoclonal antibodies, for instance, have been developed to target specific pathways or proteins involved in disease progression, offering a more precise approach to treatment with fewer side effects. For conditions like PNH, targeted therapies such as complement inhibitors have been introduced, which effectively reduce hemolysis and the risk of thrombosis, significantly improving patient outcomes. Furthermore, the integration of personalized medicine into rare hematology is enabling healthcare providers to tailor treatments based on individual genetic profiles, ensuring a higher degree of efficacy and safety. Diagnostic technologies are also evolving, with next-generation sequencing (NGS) and high-throughput screening methods making it possible to identify rare genetic mutations with greater accuracy and speed. These technological advancements are not only enhancing the precision of diagnoses but also facilitating earlier detection and intervention, which are crucial for managing rare hematologic disorders more effectively.

What Factors Are Driving The Adoption Of New Treatments In The Rare Hematology Market?

Several factors are contributing to the increased adoption of new treatments in the Rare Hematology market, including the growing prevalence of rare blood disorders, advancements in medical research, and favorable regulatory frameworks. The rising incidence of rare hematologic conditions is partly due to improved diagnostic capabilities, which have led to higher detection rates and more accurate classification of these diseases. With more patients being accurately diagnosed, there is a greater demand for innovative therapies that go beyond conventional treatments. At the same time, advancements in medical research, particularly in the fields of genomics and biotechnology, are enabling the development of more effective and targeted therapies. The success of these therapies in clinical trials has spurred pharmaceutical companies to invest heavily in rare hematology, leading to an increase in the availability of new and improved treatment options for patients.

Another key driver of treatment adoption is the supportive regulatory environment. Recognizing the unique challenges associated with developing therapies for rare diseases, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established special designations like Orphan Drug Status and Breakthrough Therapy Designation. These programs provide incentives such as extended market exclusivity, expedited review processes, and reduced regulatory fees, making it more attractive for companies to pursue drug development in the rare hematology space. Additionally, the growing influence of patient advocacy groups has led to increased awareness and better access to information about available treatments, empowering patients and their families to seek out specialized care and novel therapies. As a result, there is a rising acceptance of these new treatments, especially among patient populations that previously had limited or no therapeutic options. The combination of these factors is driving higher adoption rates and expanding the reach of new therapies within the Rare Hematology market.

What Is Driving The Growth Of The Global Rare Hematology Market?

The growth in the global Rare Hematology market is driven by several factors, including the increased focus on rare disease research, advancements in therapeutic technologies, and evolving healthcare policies. One of the primary growth drivers is the rising investment in research and development by pharmaceutical and biotechnology companies. Encouraged by favorable regulatory incentives and growing patient demand, companies are dedicating substantial resources to the discovery and development of innovative therapies for rare blood disorders. This has led to a steady pipeline of new treatments, ranging from gene therapies and enzyme replacements to next-generation biologics and small molecule drugs. The market is also benefiting from technological innovations that are enabling more effective disease modeling, drug screening, and clinical trials, thereby accelerating the development process and bringing new therapies to market more quickly.

Evolving healthcare policies are another crucial driver of market growth. Many countries have introduced national rare disease plans or policies aimed at improving the diagnosis, treatment, and care of patients with rare diseases, including hematologic conditions. These policies often include initiatives to increase research funding, support the development of specialized care centers, and improve patient access to advanced therapies. Furthermore, collaborations between academia, industry, and patient organizations are fostering a more collaborative research environment, accelerating the pace of innovation in the field. Another growth driver is the increasing prevalence of rare hematologic conditions, which is creating a larger patient pool in need of specialized treatments. Improved awareness and better diagnostic capabilities are contributing to higher diagnosis rates, which in turn are driving demand for targeted therapies and comprehensive care solutions. As these factors converge, the global Rare Hematology market is poised for continued growth, supported by a strong innovation pipeline, enhanced regulatory frameworks, and an ever-increasing focus on improving patient outcomes and quality of life.

SCOPE OF STUDY:

The report analyzes the Rare Hematology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Plasma Derived Factors, Recombinant Factors); Age Group (Adult (18+), Pediatric (0-17))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Alexion Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • CSL Behring
  • Novo Nordisk A/S
  • PRA Health Sciences
  • Shire PLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Rare Hematology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Awareness of Rare Blood Disorders Spurs Growth of the Rare Hematology Market
    • Rising Investment in Orphan Drug Development Strengthens Business Case for Rare Hematology Therapeutics
    • Advancements in Gene and Cell Therapy Propel Innovation in Rare Hematology Treatments
    • Development of Innovative Therapeutics for Hemophilia Drives Market Demand
    • Focus on Expanding Treatment Options for Sickle Cell Disease Accelerates Market Growth
    • Development of Novel Biomarkers for Blood Disorders Expands Scope of Rare Hematology Treatments
    • Emergence of Stem Cell Therapies Bodes Well for Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rare Hematology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Plasma Derived Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Recombinant Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adult (18+) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pediatric (0-17) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • JAPAN
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • CHINA
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • EUROPE
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • FRANCE
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: France 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • GERMANY
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Germany 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Italy 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: UK 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Rest of Europe 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Asia-Pacific 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of World 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of World 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030

IV. COMPETITION